BioClec, a Milan, Italy-based biotechnology company focused on breakthrough therapies for Alzheimer’s disease (AD), received an investment from Sofinnova Partners.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its R&D Efforts.
Founded by Dr. Marco Colonna and led by CEO Gabriella Camboni, BioClec is developing novel therapies targeting microglia, the brain’s immune cells, to treat Alzheimer’s disease, the most common form of dementia. AD, which affects millions worldwide, progressively impairs memory and cognitive functions, ultimately depriving patients of their ability to perform daily activities.
FinSMEs
19/03/2025